You are here

Epigen Biosciences, Inc.

Company Information
Address
10225 Barnes Canyon Road Suite A104
San Diego, CA 92121
United States


http://www.epigenbiosciences.com

Information

UEI: L1EDVCGK2327

# of Employees: 5


Ownership Information

HUBZone Owned: No

Socially and Economically Disadvantaged: No

Woman Owned: No



Award Charts




Award Listing

  1. Development of a novel therapeutic for the treatment of diabetic nephropathy and renal fibrosis

    Amount: $2,998,612.00

    SummaryThe ultimate goal of our project is to develop novel therapeutics effective in chronic kidney diseases, such as diabetic nephropathy (DN), that normally develop fibrosis, lead to end stage rena ...

    SBIRPhase II2018Department of Health and Human Services National Institutes of Health
  2. New Approach to Atopic Dermatitis

    Amount: $225,000.00

    PROJECT SUMMARYCurrent thinking has provided substantial support for the hypothesis that primary afferent and neuraxial neurogenic peptide receptors play a prominent role in pruritic pathologiesOf equ ...

    SBIRPhase I2018Department of Health and Human Services National Institutes of Health
  3. Assessment of LPA1R antagonists in animal models of NASH

    Amount: $298,946.00

    Summary The ultimate goal of this application is to develop one of Epigenandapos s proprietary antagonists of the lysophosphatidic acid receptorLPA Rfor the effective treatment of liver fibrosis assoc ...

    SBIRPhase I2018Department of Health and Human Services National Institutes of Health
  4. Novel therapy for Fragile X syndrome

    Amount: $834,798.00

    PROJECT SUMMARY Fragile X syndromeFXSis the most common inheritable form of cognitive impairment and the leading known genetic cause of autismFXS is caused by the loss of expression of the fragile X m ...

    STTRPhase I2017Department of Health and Human Services National Institutes of Health
  5. Novel Treatment for Traumatic Brain Injury

    Amount: $417,267.00

    SUMMARY Traumatic brain injury TBI is a leading contributor to death and disability in the USA yet widely effective treatments remain elusive and except for a lengthy program of rehabilitation no ...

    STTRPhase I2017Department of Health and Human Services National Institutes of Health
  6. Novel integrin inhibitors for kidney fibrosis

    Amount: $228,661.00

    DESCRIPTION provided by applicant Novel Integrin Inhibitors for Kidney Fibrosis Chronic Kidney Disease CKD currently affects over million people in the US and is a significant healthcare burde ...

    SBIRPhase I2015Department of Health and Human Services National Institutes of Health
  7. Synthesis and evaluation of novel kinase inhibitors as anti-metastasis agents for

    Amount: $225,000.00

    PROJECT SUMMARY Metastasis is a key factor for poor prognosis in cancer patients. Ovarian cancer is the fifth most common gynecological cancer causing significant mortality among women. Breast cancer ...

    SBIRPhase I2014Department of Health and Human Services National Institutes of Health
  8. Discovery of novel small molecule analgesics

    Amount: $244,999.00

    DESCRIPTION (provided by applicant): Peripheral nerve injury can lead to anomalous sensations referred to as neuropathic pain. Nerve injury may result from a variety of insults ranging from frank inju ...

    STTRPhase I2014Department of Health and Human Services National Institutes of Health
  9. Novel Therapeutic Opportunity in Stroke

    Amount: $225,000.00

    DESCRIPTION (provided by applicant): Stroke is a leading cause of death and disability in the USA, yet widely effective treatments remain elusive and, except for a lengthy program of rehabilitation, ...

    STTRPhase I2014Department of Health and Human Services National Institutes of Health
  10. Development of novel agents for the treatment of renal fibrosis adminstrative supplement

    Amount: $1,453,632.00

    DESCRIPTION provided by applicant The ultimate goal of our project is to develop novel therapeutics effective in chronic kidney diseases that normally develop fibrosis lead to end stage renal dise ...

    SBIRPhase II2014Department of Health and Human Services National Institutes of Health
US Flag An Official Website of the United States Government